Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs
Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18 F-pretomanid positron emission tomogra...
Saved in:
Published in | Nature communications Vol. 15; no. 1; pp. 6657 - 11 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
14.08.2024
Nature Publishing Group Nature Portfolio |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic
18
F-pretomanid positron emission tomography (PET) in eight human subjects to visualize
18
F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR)
Mycobacterium tuberculosis
strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration.
Antibiotic treatments for tuberculous meningitis, the deadliest form of tuberculosis, are not optimized. Here, PET in human and animal studies is used to measure the biodistribution of several antibiotics to develop optimized regimens for drug-resistant tuberculous meningitis. |
---|---|
AbstractList | Abstract Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18F-pretomanid positron emission tomography (PET) in eight human subjects to visualize 18F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration. Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18F-pretomanid positron emission tomography (PET) in eight human subjects to visualize 18F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration.Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18F-pretomanid positron emission tomography (PET) in eight human subjects to visualize 18F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration. Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic F-pretomanid positron emission tomography (PET) in eight human subjects to visualize F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration. Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18F-pretomanid positron emission tomography (PET) in eight human subjects to visualize 18F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration.Antibiotic treatments for tuberculous meningitis, the deadliest form of tuberculosis, are not optimized. Here, PET in human and animal studies is used to measure the biodistribution of several antibiotics to develop optimized regimens for drug-resistant tuberculous meningitis. Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18 F-pretomanid positron emission tomography (PET) in eight human subjects to visualize 18 F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration. Antibiotic treatments for tuberculous meningitis, the deadliest form of tuberculosis, are not optimized. Here, PET in human and animal studies is used to measure the biodistribution of several antibiotics to develop optimized regimens for drug-resistant tuberculous meningitis. |
ArticleNumber | 6657 |
Author | Peloquin, Charles A. Arun, Bhavatharini Singh, Medha Carroll, Laurence S. Mane, Kishor Nino-Meza, Oscar J. Sarhan, Mona O. Ivaturi, Vijay D. Jain, Sanjay K. Freundlich, Joel S. Shah, Maunank Jeon, Byeonghoon Chen, Xueyi Tucker, Elizabeth W. |
Author_xml | – sequence: 1 givenname: Xueyi orcidid: 0000-0003-1574-7759 surname: Chen fullname: Chen, Xueyi organization: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine – sequence: 2 givenname: Bhavatharini surname: Arun fullname: Arun, Bhavatharini organization: Center for Translational Medicine, University of Maryland School of Pharmacy – sequence: 3 givenname: Oscar J. surname: Nino-Meza fullname: Nino-Meza, Oscar J. organization: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine – sequence: 4 givenname: Mona O. surname: Sarhan fullname: Sarhan, Mona O. organization: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine – sequence: 5 givenname: Medha surname: Singh fullname: Singh, Medha organization: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine – sequence: 6 givenname: Byeonghoon orcidid: 0009-0008-3993-6486 surname: Jeon fullname: Jeon, Byeonghoon organization: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine – sequence: 7 givenname: Kishor surname: Mane fullname: Mane, Kishor organization: Department of Pharmacology, Physiology, and Neuroscience, Rutgers New Jersey Medical School – sequence: 8 givenname: Maunank surname: Shah fullname: Shah, Maunank organization: Department of Medicine, Johns Hopkins University School of Medicine – sequence: 9 givenname: Elizabeth W. surname: Tucker fullname: Tucker, Elizabeth W. organization: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine – sequence: 10 givenname: Laurence S. surname: Carroll fullname: Carroll, Laurence S. organization: Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine – sequence: 11 givenname: Joel S. orcidid: 0000-0002-3411-3455 surname: Freundlich fullname: Freundlich, Joel S. organization: Department of Pharmacology, Physiology, and Neuroscience, Rutgers New Jersey Medical School – sequence: 12 givenname: Charles A. orcidid: 0000-0001-9002-7052 surname: Peloquin fullname: Peloquin, Charles A. organization: Infectious Disease Pharmacokinetics Laboratory, Pharmacotherapy and Translational Research, University of Florida College of Pharmacy – sequence: 13 givenname: Vijay D. orcidid: 0000-0002-6433-1154 surname: Ivaturi fullname: Ivaturi, Vijay D. organization: Center for Translational Medicine, University of Maryland School of Pharmacy, Centre for Pharmacometrics, Manipal University – sequence: 14 givenname: Sanjay K. orcidid: 0000-0001-9620-7070 surname: Jain fullname: Jain, Sanjay K. email: sjain5@jhmi.edu organization: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39143055$$D View this record in MEDLINE/PubMed |
BookMark | eNp9Ustu1TAUjFARfdAfYIEisWET8CtxskKotFCpEizK2vLjJPgqsS9-VC1fj2_TQttFvfGxPTOaOceH1Z7zDqrqDUYfMKL9x8gw63iDCGtaNPRDw15UBwQx3GBO6N6Der86jnGDyqID7hl7Ve2XglHUtgfV-OXGycXq-sfpZR3gCuQca-2XrQxpAZfkbP-AqVWQ1tXSmXrObqqTjTFDOSerrE-FDtdbH3OAWPuxTllB0Hn20cbahDzF19XLsSjD8d1-VP08O708-dZcfP96fvL5otEtw6mRQEbSaoYAjGlNR2WvFSOIG8RRZ4jWaCBYG86RJIaw0Qy003ToJSjSd5IeVeerrvFyI7bBLjLcCC-tuL3wYRIlmNUzCEwUZxwIV6WHijI5Kmg5x6rf9RepovVp1dpmtYDRpRtBzo9EH784-0tM_kpgTAkbUFcU3t8pBP87Q0xisVHDPEsHPkdB0UDLhBhvC_TdE-jG5-BKr3YoMpTEPS-otw8t_fNyP88C6FeADj7GAKPQNslk_c6hnQVGYpdOrL9HlOTi9vcIVqjkCfVe_VkSXUmxgN0E4b_tZ1h_AQRR2Bo |
CitedBy_id | crossref_primary_10_3390_vaccines12121397 |
Cites_doi | 10.7554/eLife.85307 10.1128/AAC.01691-15 10.1371/journal.pone.0094462 10.1128/AAC.00021-19 10.3389/fphar.2022.1048653 10.1371/journal.pone.0105222 10.1136/jnnp.53.1.81 10.1002/cpt.646 10.1007/s40265-019-01207-9 10.1186/s13063-022-06772-1 10.1016/j.ijantimicag.2023.107048 10.1128/AAC.01354-09 10.1186/s12941-015-0107-z 10.1128/aac.00658-22 10.2967/jnumed.117.207431 10.1056/NEJMoa040573 10.1016/j.tube.2010.07.002 10.1126/scitranslmed.aau0965 10.1038/s41573-020-0080-x 10.1371/journal.pone.0270201 10.1093/cid/cix540 10.1517/17425255.2013.786042 10.1093/cid/cix230 10.1038/nrneurol.2017.120 10.1038/s41590-018-0119-x 10.1177/074823379701300401 10.1016/S1474-4422(21)00435-X 10.1128/AAC.00106-09 10.1021/acsinfecdis.9b00473 10.1038/s41591-020-0770-2 10.1111/bcp.15102 10.1128/aac.00035-23 10.1093/infdis/jit331 10.1128/AAC.01644-12 10.1172/JCI155851 10.12688/wellcomeopenres.16783.1 10.1172/JCI145107 10.1086/605576 10.1371/journal.pone.0133869 10.1128/AAC.05293-11 10.1128/AAC.04180-14 10.3390/pharmaceutics16010144 10.1007/s40262-023-01217-7 10.1056/NEJMoa1507062 10.1128/AAC.01182-08 10.1038/s41467-022-35730-3 10.1128/AAC.48.5.1441-1453.2004 10.1097/00006454-199203000-00004 10.1021/acsinfecdis.9b00207 10.1021/jm901858n 10.1016/j.resuscitation.2022.02.024 10.1128/AAC.00849-10 10.1093/cid/ciw763 10.1007/s40262-024-01363-6 |
ContentType | Journal Article |
Copyright | The Author(s) 2024 2024. The Author(s). The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7X7 7XB 88E 8AO 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P5Z P62 P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI RC3 SOI 7X8 5PM DOA |
DOI | 10.1038/s41467-024-50989-4 |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection ProQuest Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Biological Science Database Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition Genetics Abstracts Environment Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Entomology Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Immunology Abstracts Environment Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2041-1723 |
EndPage | 11 |
ExternalDocumentID | oai_doaj_org_article_12b747e27b024b34afbe5771b810380b PMC11324906 39143055 10_1038_s41467_024_50989_4 |
Genre | Journal Article Observational Study |
GrantInformation_xml | – fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) – fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) grantid: R01-AI145435-A1; R01-AI153349; R21- AI149760; K08-AI139371 funderid: https://doi.org/10.13039/100000060 – fundername: U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) grantid: R01-HL131829 funderid: https://doi.org/10.13039/100000050 – fundername: NIAID NIH HHS grantid: R01 AI153349 – fundername: U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) grantid: R01-HL131829 – fundername: NIAID NIH HHS grantid: R01 AI145435 – fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) grantid: R01-AI153349 – fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) grantid: R21- AI149760 – fundername: NIAID NIH HHS grantid: K08 AI139371 – fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) grantid: K08-AI139371 – fundername: NHLBI NIH HHS grantid: R01 HL131829 – fundername: NIAID NIH HHS grantid: R21 AI149760 – fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) grantid: R01-AI145435-A1 |
GroupedDBID | --- 0R~ 39C 3V. 53G 5VS 70F 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ AAHBH AAJSJ ABUWG ACGFO ACGFS ACIWK ACMJI ACPRK ACSMW ADBBV ADFRT ADMLS ADRAZ AENEX AEUYN AFKRA AFRAH AHMBA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH AOIJS ARAPS ASPBG AVWKF AZFZN BBNVY BCNDV BENPR BGLVJ BHPHI BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EE. EMOBN F5P FEDTE FYUFA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ KQ8 LGEZI LK8 LOTEE M1P M48 M7P M~E NADUK NAO NXXTH O9- OK1 P2P P62 PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT SV3 TSG UKHRP AASML AAYXX CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7XB 8FD 8FK AARCD AZQEC C1K DWQXO FR3 GNUQQ H94 K9. P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI RC3 SOI 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c541t-ae2f25c40eedd5d63a8cb4207d0706d2cc0921cd770a2d24fd936c398aeb286a3 |
IEDL.DBID | M48 |
ISSN | 2041-1723 |
IngestDate | Wed Aug 27 01:27:19 EDT 2025 Thu Aug 21 18:34:53 EDT 2025 Mon Jul 21 10:02:04 EDT 2025 Wed Aug 13 07:37:08 EDT 2025 Wed Feb 19 02:09:53 EST 2025 Thu Apr 24 23:04:16 EDT 2025 Tue Jul 01 02:37:27 EDT 2025 Fri Feb 21 02:39:59 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c541t-ae2f25c40eedd5d63a8cb4207d0706d2cc0921cd770a2d24fd936c398aeb286a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0002-6433-1154 0000-0001-9620-7070 0000-0001-9002-7052 0000-0002-3411-3455 0000-0003-1574-7759 0009-0008-3993-6486 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41467-024-50989-4 |
PMID | 39143055 |
PQID | 3092977087 |
PQPubID | 546298 |
PageCount | 11 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_12b747e27b024b34afbe5771b810380b pubmedcentral_primary_oai_pubmedcentral_nih_gov_11324906 proquest_miscellaneous_3093172475 proquest_journals_3092977087 pubmed_primary_39143055 crossref_citationtrail_10_1038_s41467_024_50989_4 crossref_primary_10_1038_s41467_024_50989_4 springer_journals_10_1038_s41467_024_50989_4 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-08-14 |
PublicationDateYYYYMMDD | 2024-08-14 |
PublicationDate_xml | – month: 08 year: 2024 text: 2024-08-14 day: 14 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Nature communications |
PublicationTitleAbbrev | Nat Commun |
PublicationTitleAlternate | Nat Commun |
PublicationYear | 2024 |
Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
References | Brown, Delp, Lindstedt, Rhomberg, Beliles (CR56) 1997; 13 Mota (CR7) 2022; 13 Whitfield (CR41) 2015; 10 Tucker (CR53) 2018; 10 CR39 Tasneen (CR54) 2011; 55 CR38 Lappin, Noveck, Burt (CR48) 2013; 9 Evans (CR26) 2022; 17 Tucker (CR21) 2024; 63 Ordonez (CR8) 2020; 26 Foss (CR51) 2018; 59 Ding (CR46) 2022; 66 Keam (CR10) 2019; 79 Foss, Harper, Wang, Pomper, Jain (CR11) 2013; 208 Vinnard (CR24) 2017; 64 Mehta, Guo, van der Graaf, van Hasselt (CR55) 2023; 62 Maranchick (CR37) 2022; 13 Wilkinson (CR4) 2017; 13 Tasneen (CR59) 2016; 60 Ordonez (CR6) 2021; 131 Xu (CR20) 2019; 63 Donald (CR31) 2010; 90 CR9 Ardiansyah (CR43) 2023; 12 Williams (CR61) 2009; 53 Heemskerk, Bang, Thwaites (CR42) 2016; 374 CR40 Wihersaari (CR44) 2022; 174 Ruiz-Bedoya (CR14) 2022; 132 Alffenaar (CR36) 2009; 49 Lakshminarayana (CR58) 2014; 9 Tietjen, Kroemer, Cattaneo, Baldelli, Wicha (CR57) 2022; 88 Maitre (CR17) 2022; 23 Mota (CR15) 2020; 6 Dong (CR32) 2024; 16 Torok (CR33) 2018; 103 Huynh (CR5) 2022; 21 Wallis (CR60) 2014; 9 Liu (CR35) 2010; 53 Weinstein (CR52) 2012; 56 Senbayrak (CR23) 2015; 14 Heemskerk (CR25) 2017; 65 CR50 Thwaites (CR19) 2004; 351 Diacon (CR27) 2010; 54 Li (CR47) 2023; 67 Ordonez (CR13) 2015; 59 Ordonez (CR16) 2019; 5 Ahmad (CR28) 2011; 55 Burt (CR49) 2020; 19 Jacobs, Sunakorn, Chotpitayasunonah, Pope, Kelleher (CR34) 1992; 11 Phuapradit, Supmonchai, Kaojarern, Mokkhavesa (CR30) 1990; 53 CR22 Davis (CR18) 2021; 6 Jain (CR3) 2018; 19 Rohlwink (CR45) 2017; 65 Muller, dela Pena, Derendorf (CR2) 2004; 48 Foss (CR12) 2018; 59 Ehrlich (CR1) 1913; 2 Ginsberg, Laurenzi, Rouse, Whitney, Spigelman (CR29) 2009; 53 AG Davis (50989_CR18) 2021; 6 50989_CR22 SB Lakshminarayana (50989_CR58) 2014; 9 S Dong (50989_CR32) 2024; 16 AA Ordonez (50989_CR8) 2020; 26 K Mehta (50989_CR55) 2023; 62 CA Foss (50989_CR12) 2018; 59 AA Ordonez (50989_CR13) 2015; 59 RS Wallis (50989_CR60) 2014; 9 PR Donald (50989_CR31) 2010; 90 SY Li (50989_CR47) 2023; 67 T Burt (50989_CR49) 2020; 19 RP Brown (50989_CR56) 1997; 13 AA Ordonez (50989_CR6) 2021; 131 C Vinnard (50989_CR24) 2017; 64 R Tasneen (50989_CR54) 2011; 55 E Ardiansyah (50989_CR43) 2023; 12 F Mota (50989_CR15) 2020; 6 S Senbayrak (50989_CR23) 2015; 14 EW Tucker (50989_CR21) 2024; 63 RJ Wilkinson (50989_CR4) 2017; 13 GE Thwaites (50989_CR19) 2004; 351 CA Foss (50989_CR51) 2018; 59 50989_CR50 SJ Keam (50989_CR10) 2019; 79 J Xu (50989_CR20) 2019; 63 T Maitre (50989_CR17) 2022; 23 CA Ruiz-Bedoya (50989_CR14) 2022; 132 R Tasneen (50989_CR59) 2016; 60 AK Tietjen (50989_CR57) 2022; 88 L Liu (50989_CR35) 2010; 53 50989_CR40 P Ehrlich (50989_CR1) 1913; 2 Y Ding (50989_CR46) 2022; 66 J Huynh (50989_CR5) 2022; 21 EA Weinstein (50989_CR52) 2012; 56 JW Alffenaar (50989_CR36) 2009; 49 UK Rohlwink (50989_CR45) 2017; 65 EE Evans (50989_CR26) 2022; 17 RF Jacobs (50989_CR34) 1992; 11 F Mota (50989_CR7) 2022; 13 AA Ordonez (50989_CR16) 2019; 5 P Phuapradit (50989_CR30) 1990; 53 Z Ahmad (50989_CR28) 2011; 55 ME Torok (50989_CR33) 2018; 103 AH Diacon (50989_CR27) 2010; 54 MG Whitfield (50989_CR41) 2015; 10 50989_CR9 EW Tucker (50989_CR53) 2018; 10 M Muller (50989_CR2) 2004; 48 50989_CR39 50989_CR38 KN Williams (50989_CR61) 2009; 53 G Lappin (50989_CR48) 2013; 9 NF Maranchick (50989_CR37) 2022; 13 CA Foss (50989_CR11) 2013; 208 AM Ginsberg (50989_CR29) 2009; 53 SK Jain (50989_CR3) 2018; 19 AD Heemskerk (50989_CR25) 2017; 65 AD Heemskerk (50989_CR42) 2016; 374 L Wihersaari (50989_CR44) 2022; 174 |
References_xml | – volume: 2 start-page: 445 year: 1913 end-page: 451 ident: CR1 article-title: Chemotherapeutics: scientific principles, methods, and results. Address in pathology to 17th International Congress of Medicine (London, 1913) publication-title: Lancet – ident: CR22 – volume: 12 start-page: e85307 year: 2023 ident: CR43 article-title: Tryptophan metabolism determines outcome in tuberculous meningitis: a targeted metabolomic analysis publication-title: Elife doi: 10.7554/eLife.85307 – volume: 60 start-page: 270 year: 2016 end-page: 277 ident: CR59 article-title: Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01691-15 – volume: 9 start-page: e94462 year: 2014 ident: CR60 article-title: Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis publication-title: PLoS ONE doi: 10.1371/journal.pone.0094462 – ident: CR39 – volume: 63 start-page: e00021 year: 2019 end-page: 19 ident: CR20 article-title: Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of Tuberculosis publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00021-19 – volume: 13 year: 2022 ident: CR37 article-title: Cerebrospinal fluid concentrations of fluoroquinolones and carbapenems in tuberculosis meningitis publication-title: Front Pharm. doi: 10.3389/fphar.2022.1048653 – volume: 9 start-page: e105222 year: 2014 ident: CR58 article-title: Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis publication-title: PLoS ONE doi: 10.1371/journal.pone.0105222 – volume: 53 start-page: 81 year: 1990 end-page: 82 ident: CR30 article-title: The blood/cerebrospinal fluid partitioning of pyrazinamide: a study during the course of treatment of tuberculous meningitis publication-title: J. Neurol. Neurosurg. Psychiatry doi: 10.1136/jnnp.53.1.81 – volume: 103 start-page: 449 year: 2018 end-page: 457 ident: CR33 article-title: Suboptimal exposure to Anti-TB drugs in a TBM/HIV+ population is not related to antiretroviral therapy publication-title: Clin. Pharm. Ther. doi: 10.1002/cpt.646 – volume: 79 start-page: 1797 year: 2019 end-page: 1803 ident: CR10 article-title: Pretomanid: First approval publication-title: Drugs doi: 10.1007/s40265-019-01207-9 – volume: 23 year: 2022 ident: CR17 article-title: Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial publication-title: Trials doi: 10.1186/s13063-022-06772-1 – volume: 63 year: 2024 ident: CR21 article-title: Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitis publication-title: Int J. Antimicrob. Agents doi: 10.1016/j.ijantimicag.2023.107048 – volume: 54 start-page: 3402 year: 2010 end-page: 3407 ident: CR27 article-title: Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01354-09 – volume: 14 start-page: 47 year: 2015 ident: CR23 article-title: Antituberculosis drug resistance patterns in adults with tuberculous meningitis: results of haydarpasa-iv study publication-title: Ann. Clin. Microbiol. Antimicrob. doi: 10.1186/s12941-015-0107-z – volume: 66 year: 2022 ident: CR46 article-title: Superior efficacy of a TBI-166, bedaquiline, and pyrazinamide combination regimen in a murine model of tuberculosis publication-title: Antimicrob. Agents Chemother. doi: 10.1128/aac.00658-22 – volume: 59 start-page: 1751 year: 2018 end-page: 1756 ident: CR51 article-title: Biodistribution and radiation dosimetry of (124)I-DPA-713, a PET radiotracer for macrophage-associated inflammation publication-title: J. Nucl. Med. doi: 10.2967/jnumed.117.207431 – ident: CR50 – volume: 351 start-page: 1741 year: 2004 end-page: 1751 ident: CR19 article-title: Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa040573 – ident: CR9 – volume: 90 start-page: 279 year: 2010 end-page: 292 ident: CR31 article-title: Cerebrospinal fluid concentrations of antituberculosis agents in adults and children publication-title: Tuberculosis doi: 10.1016/j.tube.2010.07.002 – volume: 10 year: 2018 ident: CR53 article-title: Noninvasive (11)C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aau0965 – volume: 19 start-page: 801 year: 2020 end-page: 818 ident: CR49 article-title: Phase 0/microdosing approaches: time for mainstream application in drug development? publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-020-0080-x – volume: 17 start-page: e0270201 year: 2022 ident: CR26 article-title: Long term outcomes of patients with tuberculous meningitis: The impact of drug resistance publication-title: PLoS ONE doi: 10.1371/journal.pone.0270201 – volume: 65 start-page: 1298 year: 2017 end-page: 1307 ident: CR45 article-title: Biomarkers of cerebral injury and inflammation in pediatric tuberculous meningitis publication-title: Clin. Infect. Dis. doi: 10.1093/cid/cix540 – volume: 9 start-page: 817 year: 2013 end-page: 834 ident: CR48 article-title: Microdosing and drug development: past, present and future publication-title: Expert Opin. Drug Metab. Toxicol. doi: 10.1517/17425255.2013.786042 – volume: 65 start-page: 20 year: 2017 end-page: 28 ident: CR25 article-title: Clinical outcomes of patients with drug-resistant Tuberculous meningitis treated with an intensified antituberculosis regimen publication-title: Clin. Infect. Dis. doi: 10.1093/cid/cix230 – volume: 13 start-page: 581 year: 2017 end-page: 598 ident: CR4 article-title: Tuberculous meningitis publication-title: Nat. Rev. Neurol. doi: 10.1038/nrneurol.2017.120 – volume: 19 start-page: 521 year: 2018 end-page: 525 ident: CR3 article-title: Tuberculous meningitis: a roadmap for advancing basic and translational research publication-title: Nat. Immunol. doi: 10.1038/s41590-018-0119-x – volume: 13 start-page: 407 year: 1997 end-page: 484 ident: CR56 article-title: Physiological parameter values for physiologically based pharmacokinetic models publication-title: Toxicol. Ind. Health doi: 10.1177/074823379701300401 – volume: 21 start-page: 450 year: 2022 end-page: 464 ident: CR5 article-title: Tuberculous meningitis: progress and remaining questions publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(21)00435-X – volume: 53 start-page: 3720 year: 2009 end-page: 3725 ident: CR29 article-title: Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00106-09 – volume: 6 start-page: 916 year: 2020 end-page: 921 ident: CR15 article-title: Radiosynthesis and biodistribution of (18)F-Linezolid in mycobacterium Tuberculosis-infected mice using positron emission tomography publication-title: ACS Infect. Dis. doi: 10.1021/acsinfecdis.9b00473 – volume: 26 start-page: 529 year: 2020 end-page: 534 ident: CR8 article-title: Dynamic imaging in patients with Tuberculosis reveals heterogeneous drug exposures in pulmonary lesions publication-title: Nat. Med. doi: 10.1038/s41591-020-0770-2 – volume: 88 start-page: 1835 year: 2022 end-page: 1844 ident: CR57 article-title: Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients publication-title: Br. J. Clin. Pharm. doi: 10.1111/bcp.15102 – volume: 67 year: 2023 ident: CR47 article-title: Next-generation diarylquinolines improve sterilizing activity of regimens with pretomanid and the novel oxazolidinone TBI-223 in a mouse tuberculosis model publication-title: Antimicrob. Agents Chemother. doi: 10.1128/aac.00035-23 – volume: 208 start-page: 2067 year: 2013 end-page: 2074 ident: CR11 article-title: Noninvasive molecular imaging of Tuberculosis-associated inflammation with radioiodinated DPA-713 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jit331 – volume: 56 start-page: 6284 year: 2012 end-page: 6290 ident: CR52 article-title: Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected mice publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01644-12 – volume: 132 start-page: e155851 year: 2022 ident: CR14 article-title: High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of Tuberculous meningitis publication-title: J. Clin. Invest. doi: 10.1172/JCI155851 – volume: 6 start-page: 136 year: 2021 ident: CR18 article-title: Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM] publication-title: Wellcome Open Res. doi: 10.12688/wellcomeopenres.16783.1 – ident: CR40 – volume: 131 start-page: e145107 year: 2021 ident: CR6 article-title: Visualizing the dynamics of Tuberculosis pathology using molecular imaging publication-title: J. Clin. Invest. doi: 10.1172/JCI145107 – volume: 64 start-page: 401 year: 2017 end-page: 407 ident: CR24 article-title: Long-term mortality of patients with Tuberculous meningitis in New York city: A cohort study publication-title: Clin. Infect. Dis. – volume: 49 start-page: 1080 year: 2009 end-page: 1082 ident: CR36 article-title: Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis publication-title: Clin. Infect. Dis. doi: 10.1086/605576 – volume: 10 start-page: e0133869 year: 2015 ident: CR41 article-title: A global perspective on pyrazinamide resistance: systematic review and meta-analysis publication-title: PLoS ONE doi: 10.1371/journal.pone.0133869 – volume: 55 start-page: 5485 year: 2011 end-page: 5492 ident: CR54 article-title: Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.05293-11 – volume: 59 start-page: 1751 year: 2018 end-page: 1756 ident: CR12 article-title: Biodistribution and radiation dosimetry of (124)I-iodo-DPA-713, a PET radiotracer for macrophage-associated inflammation publication-title: J. Nucl. Med. doi: 10.2967/jnumed.117.207431 – volume: 59 start-page: 642 year: 2015 end-page: 649 ident: CR13 article-title: Radioiodinated DPA-713 imaging correlates with bactericidal activity of Tuberculosis treatments in mice publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.04180-14 – volume: 16 start-page: 144 year: 2024 ident: CR32 article-title: Drug exposure and susceptibility of pyrazinamide correlate with treatment response in pyrazinamide-susceptible patients with multidrug-resistant tuberculosis publication-title: Pharmaceutics doi: 10.3390/pharmaceutics16010144 – ident: CR38 – volume: 62 start-page: 519 year: 2023 end-page: 532 ident: CR55 article-title: Predictions of bedaquiline and pretomanid target attainment in lung lesions of tuberculosis patients using translational minimal physiologically based pharmacokinetic modeling publication-title: Clin. Pharmacokinet. doi: 10.1007/s40262-023-01217-7 – volume: 374 start-page: 2188 year: 2016 end-page: 2189 ident: CR42 article-title: Therapy for tuberculous meningitis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1507062 – volume: 53 start-page: 1314 year: 2009 end-page: 1319 ident: CR61 article-title: Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01182-08 – volume: 13 year: 2022 ident: CR7 article-title: Dynamic (18)F-Pretomanid PET imaging in animal models of TB meningitis and human studies publication-title: Nat. Commun. doi: 10.1038/s41467-022-35730-3 – volume: 48 start-page: 1441 year: 2004 end-page: 1453 ident: CR2 article-title: Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.48.5.1441-1453.2004 – volume: 11 start-page: 194 year: 1992 end-page: 198 ident: CR34 article-title: Intensive short course chemotherapy for tuberculous meningitis publication-title: Pediatr. Infect. Dis. J. doi: 10.1097/00006454-199203000-00004 – volume: 5 start-page: 1996 year: 2019 end-page: 2002 ident: CR16 article-title: Radiosynthesis and PET bioimaging of (76)Br-Bedaquiline in a murine model of Tuberculosis publication-title: ACS Infect. Dis. doi: 10.1021/acsinfecdis.9b00207 – volume: 53 start-page: 2882 year: 2010 end-page: 2891 ident: CR35 article-title: Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons publication-title: J. Med. Chem. doi: 10.1021/jm901858n – volume: 174 start-page: 1 year: 2022 end-page: 8 ident: CR44 article-title: Neurofilament light compared to neuron-specific enolase as a predictor of unfavourable outcome after out-of-hospital cardiac arrest publication-title: Resuscitation doi: 10.1016/j.resuscitation.2022.02.024 – volume: 55 start-page: 239 year: 2011 end-page: 245 ident: CR28 article-title: PA-824 exhibits time-dependent activity in a murine model of tuberculosis publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00849-10 – volume: 374 start-page: 2188 year: 2016 ident: 50989_CR42 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1507062 – volume: 131 start-page: e145107 year: 2021 ident: 50989_CR6 publication-title: J. Clin. Invest. doi: 10.1172/JCI145107 – volume: 66 year: 2022 ident: 50989_CR46 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/aac.00658-22 – volume: 90 start-page: 279 year: 2010 ident: 50989_CR31 publication-title: Tuberculosis doi: 10.1016/j.tube.2010.07.002 – volume: 5 start-page: 1996 year: 2019 ident: 50989_CR16 publication-title: ACS Infect. Dis. doi: 10.1021/acsinfecdis.9b00207 – volume: 49 start-page: 1080 year: 2009 ident: 50989_CR36 publication-title: Clin. Infect. Dis. doi: 10.1086/605576 – volume: 79 start-page: 1797 year: 2019 ident: 50989_CR10 publication-title: Drugs doi: 10.1007/s40265-019-01207-9 – volume: 19 start-page: 801 year: 2020 ident: 50989_CR49 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/s41573-020-0080-x – volume: 63 start-page: e00021 year: 2019 ident: 50989_CR20 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00021-19 – volume: 53 start-page: 2882 year: 2010 ident: 50989_CR35 publication-title: J. Med. Chem. doi: 10.1021/jm901858n – volume: 65 start-page: 20 year: 2017 ident: 50989_CR25 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/cix230 – volume: 9 start-page: e105222 year: 2014 ident: 50989_CR58 publication-title: PLoS ONE doi: 10.1371/journal.pone.0105222 – volume: 12 start-page: e85307 year: 2023 ident: 50989_CR43 publication-title: Elife doi: 10.7554/eLife.85307 – volume: 174 start-page: 1 year: 2022 ident: 50989_CR44 publication-title: Resuscitation doi: 10.1016/j.resuscitation.2022.02.024 – volume: 9 start-page: 817 year: 2013 ident: 50989_CR48 publication-title: Expert Opin. Drug Metab. Toxicol. doi: 10.1517/17425255.2013.786042 – volume: 55 start-page: 5485 year: 2011 ident: 50989_CR54 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.05293-11 – volume: 13 start-page: 581 year: 2017 ident: 50989_CR4 publication-title: Nat. Rev. Neurol. doi: 10.1038/nrneurol.2017.120 – volume: 26 start-page: 529 year: 2020 ident: 50989_CR8 publication-title: Nat. Med. doi: 10.1038/s41591-020-0770-2 – ident: 50989_CR40 – volume: 11 start-page: 194 year: 1992 ident: 50989_CR34 publication-title: Pediatr. Infect. Dis. J. doi: 10.1097/00006454-199203000-00004 – volume: 59 start-page: 642 year: 2015 ident: 50989_CR13 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.04180-14 – volume: 59 start-page: 1751 year: 2018 ident: 50989_CR12 publication-title: J. Nucl. Med. doi: 10.2967/jnumed.117.207431 – volume: 62 start-page: 519 year: 2023 ident: 50989_CR55 publication-title: Clin. Pharmacokinet. doi: 10.1007/s40262-023-01217-7 – volume: 53 start-page: 3720 year: 2009 ident: 50989_CR29 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00106-09 – volume: 208 start-page: 2067 year: 2013 ident: 50989_CR11 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jit331 – volume: 17 start-page: e0270201 year: 2022 ident: 50989_CR26 publication-title: PLoS ONE doi: 10.1371/journal.pone.0270201 – volume: 53 start-page: 81 year: 1990 ident: 50989_CR30 publication-title: J. Neurol. Neurosurg. Psychiatry doi: 10.1136/jnnp.53.1.81 – volume: 13 start-page: 407 year: 1997 ident: 50989_CR56 publication-title: Toxicol. Ind. Health doi: 10.1177/074823379701300401 – volume: 103 start-page: 449 year: 2018 ident: 50989_CR33 publication-title: Clin. Pharm. Ther. doi: 10.1002/cpt.646 – volume: 63 year: 2024 ident: 50989_CR21 publication-title: Int J. Antimicrob. Agents doi: 10.1016/j.ijantimicag.2023.107048 – ident: 50989_CR38 – volume: 21 start-page: 450 year: 2022 ident: 50989_CR5 publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(21)00435-X – volume: 2 start-page: 445 year: 1913 ident: 50989_CR1 publication-title: Lancet – volume: 10 year: 2018 ident: 50989_CR53 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aau0965 – volume: 6 start-page: 136 year: 2021 ident: 50989_CR18 publication-title: Wellcome Open Res. doi: 10.12688/wellcomeopenres.16783.1 – ident: 50989_CR22 – volume: 56 start-page: 6284 year: 2012 ident: 50989_CR52 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01644-12 – volume: 6 start-page: 916 year: 2020 ident: 50989_CR15 publication-title: ACS Infect. Dis. doi: 10.1021/acsinfecdis.9b00473 – volume: 9 start-page: e94462 year: 2014 ident: 50989_CR60 publication-title: PLoS ONE doi: 10.1371/journal.pone.0094462 – ident: 50989_CR9 – volume: 351 start-page: 1741 year: 2004 ident: 50989_CR19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa040573 – volume: 64 start-page: 401 year: 2017 ident: 50989_CR24 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciw763 – volume: 23 year: 2022 ident: 50989_CR17 publication-title: Trials doi: 10.1186/s13063-022-06772-1 – volume: 67 year: 2023 ident: 50989_CR47 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/aac.00035-23 – volume: 55 start-page: 239 year: 2011 ident: 50989_CR28 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00849-10 – volume: 10 start-page: e0133869 year: 2015 ident: 50989_CR41 publication-title: PLoS ONE doi: 10.1371/journal.pone.0133869 – volume: 13 year: 2022 ident: 50989_CR37 publication-title: Front Pharm. doi: 10.3389/fphar.2022.1048653 – ident: 50989_CR50 – volume: 54 start-page: 3402 year: 2010 ident: 50989_CR27 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01354-09 – volume: 48 start-page: 1441 year: 2004 ident: 50989_CR2 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.48.5.1441-1453.2004 – volume: 88 start-page: 1835 year: 2022 ident: 50989_CR57 publication-title: Br. J. Clin. Pharm. doi: 10.1111/bcp.15102 – volume: 19 start-page: 521 year: 2018 ident: 50989_CR3 publication-title: Nat. Immunol. doi: 10.1038/s41590-018-0119-x – volume: 65 start-page: 1298 year: 2017 ident: 50989_CR45 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/cix540 – volume: 13 year: 2022 ident: 50989_CR7 publication-title: Nat. Commun. doi: 10.1038/s41467-022-35730-3 – ident: 50989_CR39 doi: 10.1007/s40262-024-01363-6 – volume: 16 start-page: 144 year: 2024 ident: 50989_CR32 publication-title: Pharmaceutics doi: 10.3390/pharmaceutics16010144 – volume: 53 start-page: 1314 year: 2009 ident: 50989_CR61 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01182-08 – volume: 59 start-page: 1751 year: 2018 ident: 50989_CR51 publication-title: J. Nucl. Med. doi: 10.2967/jnumed.117.207431 – volume: 132 start-page: e155851 year: 2022 ident: 50989_CR14 publication-title: J. Clin. Invest. doi: 10.1172/JCI155851 – volume: 14 start-page: 47 year: 2015 ident: 50989_CR23 publication-title: Ann. Clin. Microbiol. Antimicrob. doi: 10.1186/s12941-015-0107-z – volume: 60 start-page: 270 year: 2016 ident: 50989_CR59 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01691-15 |
SSID | ssj0000391844 |
Score | 2.4757767 |
Snippet | Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those... Abstract Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those... |
SourceID | doaj pubmedcentral proquest pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 6657 |
SubjectTerms | 59 59/78 631/326/22/1290 64 64/60 692/308/575 692/420/254 82/58 96 96/21 96/63 Adult Animals Antibiotics Antitubercular Agents - pharmacokinetics Antitubercular Agents - therapeutic use Bactericidal activity Biodistribution Brain Brain - diagnostic imaging Brain - metabolism Brain injury Compartments Disease Models, Animal Dosage Drug resistance Exposure Female Fluorine isotopes Head injuries Humanities and Social Sciences Humans Lung - diagnostic imaging Lung - metabolism Lungs Male Mass spectrometry Mass spectroscopy Meningitis Mice multidisciplinary Multidrug resistance Mycobacterium tuberculosis - drug effects Partitioning Penetration resistance Pharmacokinetics Positron emission Positron emission tomography Positron-Emission Tomography - methods Rabbits Science Science (multidisciplinary) Tissue Distribution Tissues Tuberculosis Tuberculosis, Meningeal - diagnostic imaging Tuberculosis, Meningeal - drug therapy Tuberculosis, Multidrug-Resistant - diagnostic imaging Tuberculosis, Multidrug-Resistant - drug therapy |
SummonAdditionalLinks | – databaseName: DOAJ Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bi9UwEA6yIPgi3q2uEsE3DZtbm_TRyy6LoPiwC_sWcqseOLTLaQvqr3eS9Bz3eH3xse0kDHPJzDTJNwg9h5gM_GlGvHOByKAYsbZrSM2U9t4xp2i6KPz-Q3N6Lt9d1BdXWn2lM2EFHrgI7ohxBxlv5MpBNHFC2s7FWinmdIL2pi6tvhDzrhRTeQ0WLZQucrklA4RHo8xrAkxCIEbqlsi9SJQB-3-XZf56WPKnHdMciE5uoZtLBolfFc5vo2uxv4Oul56SX--i7m3pMY8_Hp_hhM8E9oXLSfOpAPmvvsWAXWoNgW0f8BrcHU9Z_vCcrpAMMDOOXy6H9PdwxEOHp9nFjZ_Xw7gacdjMn8Z76Pzk-OzNKVmaKRBfSzYRG3nHay8pBMVQh0ZY7Z3kVAVw-iZw72nLmQ9KUcsDl11oReNFqy3U3rqx4j466Ic-PkQYBisVm9jJrpMR6qmaRk61t8pZq0WoENsK1vgFaTw1vFibvOMttCnKMKAMk5VhZIVe7MZcFpyNv1K_TvraUSaM7PwCLMcslmP-ZTkVOtxq2yyOOxoBUoCUmGpVoWe7z-ByaR_F9nGYMw1kXVyqukIPinHsOAG7yyBqFdJ7ZrPH6v6XfvU5w3ozBsltS5sKvdxa2A--_iyLR_9DFo_RDZ5cI2H9ykN0MG3m-ASyrck9zY71HUBTJko priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96Ivgifl_1lAi-abgkTZvsk_hxxyEoPtzBvoV89VxY2nXbgvrXO0mzPdaPe2ybhGlmJjOZTH6D0CuwyUCfYsRZ64nwkhFjmppUTCrnLLOSxovCn7_UZxfi07Ja5oBbn9Mqd2tiWqh952KM_LikYMilpEq-3XwnsWpUPF3NJTRuolsRuiymdMmlnGMsEf1cCZHvytBSHfcirQxgmAhYSrUgYs8eJdj-f_maf6dM_nFumszR6T10N_uR-N3E-PvoRmgfoNtTZcmfD1Hzcao0j7-enOOI0gRShqd882GC81_9Ch7bWCACm9bjNSg9HhIX4DleJOlgZBx-bLoYQ-xx1-BhtGHrxnXXr3rst-Nl_whdnJ6cfzgjuaQCcZVgAzGBN7xygoJp9JWvS6OcFZxKD6pfe-4cTDNzHibacM9F4xdl7cqFMrADV7UpH6ODtmvDIcLQWcpQh0Y0jQiwq6po4FQ5I60xqvQFYruJ1S7jjceyF2udzr1LpSdmaGCGTszQokCv5z6bCW3j2tbvI7_mlhEpO73otpc6K55m3MKOKXBpoacthWlsqKRkVsVRqS3Q0Y7bOqtvr6-ErUAv58-gePE0xbShG1Mb8L24kFWBnkzCMVMCcpeg1Aqk9sRmj9T9L-3qWwL3Zgxc3AWtC_RmJ2FXdP1_Lp5e_xvP0B0ehT5i-YojdDBsx_AcvKnBvkgq8xvttR6t priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9UwEB7WFcEX8W51lQi-aTFJ0yZ91OMui6D4sAv7FnLreuDQLqctqL_eSdoeOboKPradCcNcOpPbNwCvMCejfIrlzlqfCy9ZbkxT5SWTyjnLrKTxovCnz9Xpufh4UV4cAF_uwqRD-wnSMv2ml9Nhb3uRQhozSo4pTtW5uAE3I3R79OpVtdqtq0TEcyXEfD-GFuoa1r0clKD6r6sv_zwm-dteaUpBJ3fhzlw7kneTtPfgILT34dbUTfL7A2g-TN3lyZfjMxKRmdCzyHTGfJgg_Nc_gic2NoUgpvVkg4FOhqR5fI6XRzocmYRvV11cN-xJ15BhtGHrxk3Xr3vit-Nl_xDOT47PVqf53EYhd6VgQ24Cb3jpBMV06EtfFUY5KziVHsO98tw5WnPmvJTUcM9F4-uickWtDM66VWWKR3DYdm14AgSZpQxVaETTiIAzqZIGTpUz0hqjCp8BWxSr3YwxHltdbHTa6y6Unoyh0Rg6GUOLDF7veK4mhI1_Ur-P9tpRRnTs9KLbXurZWzTjFmdJgUuLnLYQprGhlJJZFUelNoOjxdp6DtleF6gFLIapkhm83H3GYIs7KKYN3ZhosN7iQpYZPJ6cYycJ-l2CT8tA7bnNnqj7X9r11wTozRiWtTWtMnizeNgvuf6ui6f_R_4MbvMYBBHPVxzB4bAdw3OsqAb7IoXQT0O3HHc priority: 102 providerName: Springer Nature |
Title | Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs |
URI | https://link.springer.com/article/10.1038/s41467-024-50989-4 https://www.ncbi.nlm.nih.gov/pubmed/39143055 https://www.proquest.com/docview/3092977087 https://www.proquest.com/docview/3093172475 https://pubmed.ncbi.nlm.nih.gov/PMC11324906 https://doaj.org/article/12b747e27b024b34afbe5771b810380b |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZ2EWgviDuBURmJNwjEjhM7Dwh1pWWqtGmCVepb5FtGpSoZTSpt_HqOnaSoUHjgJVHiS6xz8Tkntr-D0GuwyTA-QUKtlAmZ4SSUskjDhHChtSKKR-6g8Nl5ejpj03ky30N9uqOOgPXO0M7lk5qtlu9uvt9-BIX_0B4ZF-9r5tUdrE0I5k9kIdtHh2CZuFPUs87d9zNznEFAw7qzM7ubHqG7UMsDYW2ZKo_ov8sN_XM35W9Lqt5STe6je52LiYetTDxAe7Z8iO60SSdvH6HiU5uEHl-ML7EDcAJC4HYretMi_S9-WIOVyx2BZWnwEuYD3HgGwbM7Y1JBz9jeXFfu92KNqwI3a2VXer2s6kWNzWp9VT9Gs8n4cnQadtkWQp0w0oTS0oImmkVgNU1i0lgKrRiNuIFZITVU6yijRBvOI0kNZYXJ4lTHmZAQnItUxk_QQVmV9hnC0Jhzm9qCFQWzEHAlkaWR0JIrKUVsAkR6wua6gyJ3GTGWuV8Sj0Xe8iUHvuSeLzkL0JtNm-sWiOOftU8cvzY1HYi2f1GtrvJOJ3NCFQRTlnIFLVXMZKFswjlRwvUaqQAd99zOe8HMY6AC-MyR4AF6tSkGnXQLLbK01drXAbeMMp4E6GkrHJuR9MIVILElNltD3S4pF9887jch4P1mURqgt72E_RrX32nx_P-_9AIdUacbDgKYHaODZrW2L8EJa9QA7fM5h6uYfB6gw-Fw-nUK95Px-cUXeDtKRwP_e2PgNfAnq7A2Dg |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9QwFLZKEYILYi2BAkaCE0R1HCf2HBAC2mpKF3GYSnMz3lJGGiXDJBGUH8Vv5NlJphqW3nqcie04ft9bvL0PoZfgk6F_IomN1jZmliexUkUeZwkXxuhEc-IvCh-f5ONT9mmaTTfQr-EujD9WOdjEYKhtZfwa-U5KwJFzTgR_t_gWe9Yov7s6UGh0sDh0599hyla_PdgF-b6idH9v8nEc96wCsclY0sTK0YJmhhHwDjazeaqE0YwSbgH9uaXGwJsSY-FdilrKCjtKc5OOhIJJqMhVCu1eQ9fB8RKvUXzKV2s6Ptu6YKy_m0NSsVOzYInAEcbgmcUoZmv-L9AE_Cu2_fuI5h_7tMH97d9Bt_u4Fb_vgHYXbbjyHrrRMVme30fFbsdsjz_vTbDPCgWoxt359qajD5j9dBZrT0iBVWnxHIwMboLU4be_uFJBy9j9WFR-zbLGVYGbVrulaedVPauxXbZn9QN0eiWD_RBtllXpHiEMlTl3uStYUTAHs7iMOEqEUVwrJVIboWQYWGn6_OaeZmMuwz57KmQnDAnCkEEYkkXo9arOosvucWnpD15eq5I-M3f4o1qeyV7RZUI1zNAc5Rpq6pSpQruM80QL3yrREdoepC17c1HLC3BH6MXqMSi6371RpavaUAZiPcp4FqGtDhyrngDuQuq2CIk12Kx1df1JOfsakoknCYTUI5JH6M2AsIt-_X8sHl_-Gc_RzfHk-EgeHZwcPkG3qFcAn0eYbaPNZtm6pxDJNfpZUB-Mvly1vv4GRzdcQg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEIgXxJ3AACPBE0SNHSd2HxACumpjMO1hk_pmfMuoVCWlSQTjp_HrOHaSTuWytz22sR3H5zsX386H0AvwydA_QWKjtY2Z5SRWqsjjjHBhjCaaJ_6i8OfDfO-EfZxlsy30a7gL449VDjYxGGpbGb9GPkoTcOScJ4KPiv5YxNFk-nb5LfYMUn6ndaDT6CBy4M6-w_StfrM_AVm_pHS6e_xhL-4ZBmKTMdLEytGCZoYl4ClsZvNUCaMZTbgFTcgtNQbeSoyF9ypqKSvsOM1NOhYKJqQiVym0ewVd5WlGvI7xGV-v7_jM64Kx_p5OkopRzYJVAqcYg5cW45ht-MJAGfCvOPfv45p_7NkGVzi9hW72MSx-14HuNtpy5R10rWO1PLuLiknHco-Pdo-xzxAFCMfdWfemoxKY_3QWa09OgVVp8QIMDm4CAuC3v8RSQcvY_VhWfv2yxlWBm1a7lWkXVT2vsV21p_U9dHIpg30fbZdV6R4iDJU5d7krWFEwBzO6LHE0EUZxrZRIbYTIMLDS9LnOPeXGQoY991TIThgShCGDMCSL0Kt1nWWX6ePC0u-9vNYlfZbu8Ee1OpW90ktCNczWHOUaauqUqUK7jHOihW810RHaGaQte9NRy3OgR-j5-jEovd_JUaWr2lAG4j7KeBahBx041j0B3IU0bhESG7DZ6Ormk3L-NSQWJwTC63GSR-j1gLDzfv1_LB5d_BnP0HXQVPlp__DgMbpBPf59SmG2g7abVeueQFDX6KdBezD6ctnq-ht-MmB4 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dynamic+PET+reveals+compartmentalized+brain+and+lung+tissue+antibiotic+exposures+of+tuberculosis+drugs&rft.jtitle=Nature+communications&rft.au=Chen%2C+Xueyi&rft.au=Arun%2C+Bhavatharini&rft.au=Nino-Meza%2C+Oscar+J.&rft.au=Sarhan%2C+Mona+O.&rft.date=2024-08-14&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2041-1723&rft.volume=15&rft_id=info:doi/10.1038%2Fs41467-024-50989-4&rft_id=info%3Apmid%2F39143055&rft.externalDocID=PMC11324906 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon |